Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ani Pharmaceuticals Inc. (ANIP:NASDAQ), powered by AI.
Ani Pharmaceuticals Inc. is currently trading at $83.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Ani Pharmaceuticals Inc. on Alpha Lenz.
Ani Pharmaceuticals Inc.'s P/E ratio is 21.2.
“Ani Pharmaceuticals Inc. trades at a P/E of 21.2 (fair value) with strong ROE of 16.2%. 3Y revenue CAGR of 40.8% highlights clear growth momentum.”
Ask for details →Ani Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing high-quality generic and branded pharmaceutical products. The company operates primarily within the healthcare sector, addressing niche markets that are often underserved, thus ensuring a vital role in providing alternative options to more expensive treatments. Ani Pharmaceuticals Inc. emphasizes product development and the commercialization of unique therapies, with a growing portfolio that includes both complex generics and branded pharmaceuticals. Their product line covers areas such as endocrinology, oncology, and dermatology, providing critical solutions and serving specialized medical needs. With manufacturing facilities based in the United States, Ani Pharmaceuticals continues to strengthen its market presence through strategic acquisitions and partnerships, holding a significant position in the pharmaceutical industry as a reliable source of vital medications.
“Ani Pharmaceuticals Inc. trades at a P/E of 21.2 (fair value) with strong ROE of 16.2%. 3Y revenue CAGR of 40.8% highlights clear growth momentum.”
Ask for details →Ani Pharmaceuticals Inc. (ticker: ANIP) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 897 employees. Market cap is $1.7B.
The current price is $83 with a P/E ratio of 21.25x and P/B of 3.08x.
ROE is 16.16% and operating margin is 9.20%. Annual revenue is $883M.